These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 24055214)

  • 21. CNS Target Identification and Validation: Avoiding the Valley of Death or Naive Optimism?
    Hutson PH; Clark JA; Cross AJ
    Annu Rev Pharmacol Toxicol; 2017 Jan; 57():171-187. PubMed ID: 27575715
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neuroimaging in psychiatric disorders.
    Masdeu JC
    Neurotherapeutics; 2011 Jan; 8(1):93-102. PubMed ID: 21274689
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimizing Central Nervous System Drug Development Using Molecular Imaging.
    Hargreaves RJ; Hoppin J; Sevigny J; Patel S; Chiao P; Klimas M; Verma A
    Clin Pharmacol Ther; 2015 Jul; 98(1):47-60. PubMed ID: 25869938
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Imaging in the cardiovascular and metabolic disease area.
    Comley RA; Kallend D
    Drug Discov Today; 2013 Feb; 18(3-4):185-92. PubMed ID: 23032726
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Target engagement in lead generation.
    Durham TB; Blanco MJ
    Bioorg Med Chem Lett; 2015 Mar; 25(5):998-1008. PubMed ID: 25630223
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metabotropic glutamate receptor 5 - a promising target in drug development and neuroimaging.
    Pillai RL; Tipre DN
    Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1151-70. PubMed ID: 26743895
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Translational CNS medicines research.
    Palmer AM; Alavijeh MS
    Drug Discov Today; 2012 Oct; 17(19-20):1068-78. PubMed ID: 22580061
    [TBL] [Abstract][Full Text] [Related]  

  • 28. True alignment of preclinical and clinical research to enhance success in CNS drug development: a review of the current evidence.
    Goetghebeur PJ; Swartz JE
    J Psychopharmacol; 2016 Jul; 30(7):586-94. PubMed ID: 27147593
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Translational imaging of lymphatics in cancer.
    Cohen SM; Fishinghawk BG; Cohen MS
    Adv Drug Deliv Rev; 2011 Sep; 63(10-11):956-62. PubMed ID: 21683745
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Overview of the use of transgenic animals in CNS drug discovery.
    Nestler EJ; Olivier B
    Curr Protoc Pharmacol; 2001 May; Chapter 5():Unit5.20. PubMed ID: 21965073
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of PET and SPECT probes for glutamate receptors.
    Fuchigami T; Nakayama M; Yoshida S
    ScientificWorldJournal; 2015; 2015():716514. PubMed ID: 25874256
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The application of positron emission tomography (PET) imaging in CNS drug development.
    Suridjan I; Comley RA; Rabiner EA
    Brain Imaging Behav; 2019 Apr; 13(2):354-365. PubMed ID: 30259405
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Validation of experimental medicine methods in psychiatry: the P1vital approach and experience.
    Dawson GR; Craig KJ; Dourish CT
    Biochem Pharmacol; 2011 Jun; 81(12):1435-41. PubMed ID: 21440531
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CNS drug development. Part I: The early period of CNS drugs.
    Preskorn SH
    J Psychiatr Pract; 2010 Sep; 16(5):334-9. PubMed ID: 20859110
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CNS drug development: part III: future directions.
    Preskorn SH
    J Psychiatr Pract; 2011 Jan; 17(1):49-52. PubMed ID: 21266894
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Animal tumor models for PET in drug development.
    Toyohara J; Ishiwata K
    Ann Nucl Med; 2011 Dec; 25(10):717-31. PubMed ID: 21879295
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The value of PET ligand discovery to CNS drug development.
    Schmidt ME; Andrés JI
    Future Med Chem; 2017 Mar; 9(4):351-356. PubMed ID: 28263084
    [No Abstract]   [Full Text] [Related]  

  • 38. Challenges in developing drugs for neurological and psychiatric disorders.
    Simon NG; Brownstein MJ
    Prog Neurobiol; 2017 May; 152():1-2. PubMed ID: 28442128
    [No Abstract]   [Full Text] [Related]  

  • 39. Back to the future of psychopharmacology: A perspective on animal models in drug discovery.
    Hendriksen H; Groenink L
    Eur J Pharmacol; 2015 Jul; 759():30-41. PubMed ID: 25814259
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is pharma running out of brainy ideas?
    Miller G
    Science; 2010 Jul; 329(5991):502-4. PubMed ID: 20671165
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.